Pilar Martín

Dr. Pilar Martín

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in Molecular Cell
Verified
Journal Article
Closed access
MLMichael Leitges
Michael Leitges
LSLaura Sanz
Laura Sanz
PMPilar Martín
Pilar Martín
ADAngeles Duran
Angeles Duran
UBUschi Braun
Uschi Braun
JMJorge Moscat
Jorge Moscat

1 December 2001 in Trends in Immunology
Verified
Journal Article
Closed access
CACarlos Ardavı́n
Carlos Ardavı́n
GHGloria Martı́nez del Hoyo
Gloria Martı́nez del Hoyo
PMPilar Martín
Pilar Martín
FAFabienne Anjuère
Fabienne Anjuère
CACristina F Arias
Cristina F Arias
HHHéctor Hernández
Héctor Hernández

15 July 2002 in Blood
Verified
Journal Article
Closed access
PDF file
PMPilar Martín
Pilar Martín
GHGloria Martı́nez del Hoyo
Gloria Martı́nez del Hoyo
FAFabienne AnjuèrE
Fabienne AnjuèrE
CACristina FernánDez Arias
Cristina FernánDez Arias
HHHector Hernandez-Vargas
Hector Hernandez-Vargas
CACarlos Ardavı́n
Carlos Ardavı́n
Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Imatinib (Glivec, formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl tyrosine kinase. A total of 260 patients with CML were enrolled in a phase II trial, of whom 229 had a confirmed diagnosis of CML in blast crisis. Patients were treated with imatinib in daily oral doses of 400 mg or 600 mg. Imatinib induced hematologic responses in 52% of patients and sustained hematologic responses lasting at least 4 weeks in 31% of patients, including complete hematologic responses in 8%. For patients with a sustained response, the estimated median response duration was 10 months. Imatinib induced major cytogenetic responses in 16% of patients, with 7% of the responses being complete. Median survival time was 6.9 months. Nonhematologic adverse reactions were frequent but generally mild or moderate. Episodes of severe cytopenia were also frequent and were attributable to the underlying condition and treatment with imatinib. Drug-related adverse events led to discontinuation of therapy in 5% of patients, most often because of cytopenia, skin disorders, or gastrointestinal reactions. These results demonstrate that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis. Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs.

1 October 2013 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
RGRoberto González-Amaro
Roberto González-Amaro
JCJosé R. Cortés
José R. Cortés
FSFrancisco Sánchez-Madrid
Francisco Sánchez-Madrid
PMPilar Martín
Pilar Martín

27 May 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
RBRafael Blanco-Domínguez
Rafael Blanco-Domínguez
RSRaquel Sánchez-Díaz
Raquel Sánchez-Díaz
HFHortensia de la Fuente
Hortensia de la Fuente
LJLuis J. Jiménez-Borreguero
Luis J. Jiménez-Borreguero
AMAdela Matesanz-Marín
Adela Matesanz-Marín
PMPilar Martín
Pilar Martín
The diagnosis of acute myocarditis typically requires either endomyocardial biopsy (which is invasive) or cardiovascular magnetic resonance imaging (which is not universally available). Additional approaches to diagnosis are desirable. We sought to identify a novel microRNA for the diagnosis of acute myocarditis.

28 February 2002 in Nature
Verified
Journal Article
Closed access
GHGloria Martínez del Hoyo
Gloria Martínez del Hoyo
PMPilar Martín
Pilar Martín
HHHector Hernandez-Vargas
Hector Hernandez-Vargas
SRSara Ruiz
Sara Ruiz
CACristina Fernández Arias
Cristina Fernández Arias
CACarlos Ardavín
Carlos Ardavín